The following is a statement from Frank R. Oakes, Stellar's Chairman of the Board, President and Chief Executive Officer:
We would like to extend our congratulations to Neovacs on the encouraging results achieved in its Phase 2b study and on the continuing advancement of their IFN-Alpha-Kinoid immunotherapy in systemic lupus erythematosus, which the Lupus Foundation has described as 'one of the world's cruelest, most unpredictable and devastating diseases.' In addition to achieving key endpoints, Neovacs reported potent and long-lasting biological activity of their therapeutic vaccine, which utilizes Stellar KLH as a carrier molecule. The KLH-conjugated vaccine also demonstrated a favorable safety profile among study participants. The conclusion of this study is an important milestone for Neovacs as well as for Stellar. We believe these results will help to reinforce the role of Stellar KLH as a key component in immunotherapy treatments.
We look forward to working with Neovacs as it prepares for its pivotal Phase 3 clinical studies. Stellar remains focused and fully committed to ensuring the environmentally sound production of KLH to meet the increased volumes required by Neovacs for Phase 3 trials, manufacturing validation and scale-up.
About Stellar BiotechnologiesBased north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccine pipelines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function. KLH can also be used in immunotoxicology studies for monitoring the immunomodulatory effects of drug candidates. Stellar is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and supporting the development of KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Stellar Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; changes in trade policy and international law; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.
View original content:http://www.prnewswire.com/news-releases/stellar-issues-statement-on-favorable-clinical-study-results-300676397.html
SOURCE Stellar Biotechnologies, Inc.
